ITAbMed's CD19m-CD3 Bispecific Antibody Accepted for Clinical Trial Review by China's CDE

On June 10, 2026, the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) announced that it has accepted the clinical trial application for a recombinant anti-CD19m-CD3 antibody injection (Acceptance No. CXSL2600625) submitted by ITAbMed Ltd. The product is classified as a Class 1 innovative drug.

Accendatech Co., Ltd. Files for IPO Tutoring with CICC

Accendatech Co., Ltd. has recently completed the filing for IPO tutoring with the Tianjin Office of the China Securities Regulatory Commission (CSRC). China International Capital Corporation (CICC) has been appointed as the company's IPO tutoring institution.

Ventus Therapeutics Announces First Patient Dosed in Phase 2 Clinical Trial of VENT-03, a Novel Small Molecule cGAS Inhibitor, in Patients with Lupus

ENT-03 is the most advanced oral small molecule cGAS inhibitor in clinical development. This trial aims to demonstrate the proof-of-concept efficacy and safety of VENT-03 in lupus, and to showcase its potential in other immune-inflammatory diseases and cardiovascular diseases.

Ventus Therapeutics Announces Nomination of VENT-04, a First-in-Class, Oral, Small-Molecule Caspase-4/5 Inhibitor, as a Development Candidate

WALTHAM, Mass. & MONTREAL — January 7, 2026 — (BUSINESS WIRE) — Ventus Therapeutics, a clinical-stage biopharmaceutical company advancing multiple small-molecule programs for autoimmune, inflammatory, and neurological disorders......

Yifan Pharmaceuticals bets on the "blank track" of small cell lung cancer brain metastasis, introducing ACT001 with an initial payment of 100 million yuan | Quick Read Announcement

Yifan Pharmaceutical Co., Ltd. issued an announcement stating that Yifan Pharmaceutics Co., Ltd., its wholly-owned subsidiary, has signed an agreement with Accendatech Pharmaceutical and Tianjin Accendatech. The parties plan to introduce Class 1 innovative drug ACT001 via a RMB 100 million upfront payment plus tiered sales royalties......

Accendatech : Challenging Global Medical Challenges with Original Drugs

In March of this year, Tianjin Municipality released the second batch of specialized and innovative SMEs recognized in 2023, and Accendatech was on the list. Also in this month, its wholly-owned subsidiary, Accendatech (Tianjin) Biopharmaceutical Co., Ltd. was registered and established in Tianjin.

Yifan Pharmaceuticals subsidiary, Yifan Pharma, signed an exclusive agreement for an innovative drug.

According to Zhitong Finance APP, Yifan Pharmaceutical (002019.SZ) announced that its wholly-owned subsidiary, Yifan Pharmaceutics, has signed exclusive agreements with Accendatech and Tianjin Accendatech respectively.

Accendatech ACT001 Enters Global Pediatric Brain Tumor Clinical Trials

Following its recognition as a "Breakthrough Therapy Product in China," its inclusion in the "National Key Small Giant Enterprise" program and the "Disruptive Technology Library of the Beijing-Tianjin-Hebei National Technology Innovation Center," and its receipt of the "Excellent Award" in the 2025 National Disruptive Technology Competition, Accendatech Pharmaceutical has achieved significant success.

Interview with Professor Li Jie of Proteint Biotechnology: A scalpel or a medical technology ?

China's rapid development in the medical field in recent years is evident to all, and its technology in oncology is relatively mature. This includes establishing precise mechanisms for tumor risk assessment, prediction and early warning, early screening, classification, personalized treatment, and prediction and monitoring of efficacy and safety.

China's first! A domestically developed anti-brain tumor drug candidate receives FDA designation for rare childhood diseases in the United States.

Recently, ACT001, an original candidate drug for treating glioma developed by Professor Chen Yue's research group at Nankai University and Tianjin Accendatech Pharmaceutical Technology Co., Ltd. received Rare Childhood Disease Designation (RPDD) from the U.S. Food and Drug Administration (FDA), becoming the first original candidate drug from my country to obtain RPDD designation in the United States.

Behind the policy support, what is hindering the development of original drugs?

Original drugs address patient needs for which there are currently no treatments available; they are truly new drugs with immense clinical value, and domestic patients are the first to benefit. Original drugs represent the area in the biopharmaceutical industry where patients experience the greatest value. Recently, the American College of Clinical Oncology...

Tianjin Accendatech: A Dark Horse on the Road to "Made in China"

Stepping into Room 927, Building C, Gongfang Times, located on Lanyuan Road in the Huayuan Industrial Zone, the blue characters of Tianjin Accendatech Pharmaceutical Technology Co., Ltd.(hereinafter referred to as "Accendatech") immediately catch the eye. This is a company located in the Tianjin Binhai High-tech Industrial Development Zone.